RAPS RAC, ACRP/SOCRA, MPJE & ASQ CQE: practice drill
10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.
Timed mock exam
21 questions in 25 minutes, drawn from every topic. No answers shown until the end, then a full score breakdown, your weakest topics and a review of what you missed.
Prices are in US dollars, plus tax where it applies. Stripe, our payment processor, calculates tax at checkout.
All sales are final. If something is really wrong, such as a duplicate charge or a purchase that does not unlock what you bought, write to support@careerexampro.com and we will put it right.
One-time payment. Nothing renews.
You have an exam ticket for this practice test. Start the timed mock exam to use it.
Exact question counts, passing scores, and allowed reference materials vary by testing window and state/agency. Always confirm current rules with the official testing provider.
Sample questions
A medical device manufacturer discovers that a packaging seal defect on a single lot of sterile implantable cardiac leads compromises sterility and creates a reasonable probability of life-threatening endocarditis or death if implanted. The firm initiates a voluntary field removal. How will FDA classify this recall under 21 CFR Part 7, and what Part 806 reporting obligation applies?
Class II recall because the defect affects sterile packaging rather than electrical performance, with no Part 806 report needed.
Class III recall because the firm initiated the removal voluntarily before an FDA order, requiring only an internal CAPA log entry.
Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.
Market withdrawal rather than a recall because no patients have developed infection yet, requiring FDA notice within 30 calendar days.
Show the answer
C. Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.
Under 21 CFR 7.3(m), a Class I recall applies when there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death—a compromised sterile barrier on an implantable cardiac lead clearly meets this threshold. Additionally, under 21 CFR 806.10, a device manufacturer must submit a written report to FDA within 10 working days of initiating any correction or removal conducted to reduce a risk to health posed by the device (unless the same event was already reported under Part 803).
A hospital pharmacy receives a shipment of high-cost oncology biologics from an authorized wholesale distributor. During receiving verification under the Drug Supply Chain Security Act (DSCSA), the pharmacy technician detects tampered seals and a 2D GS1 DataMatrix product identifier whose serial number does not match the manufacturer's verification database. Subsequent investigation confirms the product is counterfeit (illegitimate). What mandatory DSCSA actions and timelines apply?
Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.
Return the counterfeit vials to the wholesaler for credit within 72 hours and notify FDA only if a patient receives a dose.
Quarantine the vials, notify FDA within 15 calendar days via MedWatch Form 3500A, and retain transaction records for 2 years.
Destroy the vials immediately using DEA Form 41 to prevent diversion, then file an annual report with the State Board of Pharmacy.
Show the answer
A. Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.
Under DSCSA (FDCA Section 582), trading partners must verify product identifiers (NDC, serial number, lot number, and expiration date in a 2D DataMatrix barcode) and immediately quarantine any suspect product during investigation. Once a product is determined to be illegitimate (e.g., counterfeit, diverted, or stolen), the dispenser must notify FDA (via Form FDA 3911) and all immediate trading partners that may have received it within 24 hours of making the determination, and must retain investigation and transaction records for at least 6 years.
A biopharmaceutical sponsor submits an original commercial Investigational New Drug (IND) application to FDA CDER for a first-in-human Phase 1 small-molecule oncology study on June 1. On June 26, FDA calls the sponsor to impose a Clinical Hold because the preclinical toxicology package lacks adequate margin-of-safety data to justify the starting dose. Which statement accurately describes the regulatory status under 21 CFR Part 312?
The sponsor may dose subjects on July 1 while addressing toxicology questions, since FDA did not send a written letter within 15 days.
The sponsor may enroll subjects at sites whose IRBs approved the protocol, because IRB approval overrides an oral FDA hold.
The sponsor must withdraw the IND and wait 180 days before filing a new application under another drug name.
The hold takes effect immediately, and no subjects may be dosed until the sponsor files a Complete Response and FDA lifts it.
Show the answer
D. The hold takes effect immediately, and no subjects may be dosed until the sponsor files a Complete Response and FDA lifts it.
Under 21 CFR 312.40(b), an IND goes into effect 30 calendar days after FDA receives it unless FDA notifies the sponsor earlier or imposes a Clinical Hold under 21 CFR 312.42. A Clinical Hold takes effect immediately upon FDA's telephone or rapid communication (followed by a written letter within 30 calendar days). While on hold, no human subjects may be given the investigational drug until the sponsor submits a Complete Response addressing all deficiencies and FDA notifies the sponsor that the hold is lifted (FDA responds within 30 calendar days of receiving the Complete Response).
Reference: 21 CFR 312.40 & 21 CFR 312.42 (IND Effective Date and Clinical Holds)
Taking this exam soon?
Tell us which exam domains or calculation drills you want more practice on.